{"nctId":"NCT02988882","briefTitle":"OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis","startDateStruct":{"date":"2015-06"},"conditions":["Chronic Allergic Conjunctivitis"],"count":86,"armGroups":[{"label":"OTX-DP","type":"EXPERIMENTAL","interventionNames":["Drug: Dexamethasone"]},{"label":"PV","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo Vehicle"]}],"interventions":[{"name":"Dexamethasone","otherNames":[]},{"name":"Placebo Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a positive history of ocular allergies and a positive skin test reaction to a perennial allergen and a seasonal allergen\n* Has a positive bilateral CAC reaction to a perennial allergen within minutes of instillation\n\nExclusion Criteria:\n\n* History of refractive surgery (including LASIK procedures) within the past 2 years\n* History of retinal detachment, diabetic retinopathy, or active retinal disease\n* Presence of an active ocular infection or positive history of an ocular herpetic infection at any visit\n* Use any of the disallowed medications during the period indicated\n* History of IOP increase as a result of steroid treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6","description":"Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":"1.088"},{"groupId":"OG001","value":"2.31","spread":"1.115"}]}]}]},{"type":"PRIMARY","title":"Ocular Itching Post-CAC (Conjunctival Allergan Challenge) at Visit 6","description":"Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.07","spread":"1.100"},{"groupId":"OG001","value":"2.41","spread":"1.039"}]}]}]},{"type":"PRIMARY","title":"Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6","description":"Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"1.131"},{"groupId":"OG001","value":"2.37","spread":"1.129"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":["Adverse Events"]}}}